Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market Facility
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451
Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform
Quebec Innovative Materials:Advancing Canadian and American Natural Hydrogen for the Next Energy Cycle
